CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alumis Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alumis Inc
280 East Grand Avenue
Phone: (650) 231-6625p:650 231-6625 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: ALMSALMS
Business Summary
Alumis Inc. is a clinical-stage biopharmaceutical company. It develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. It has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer MartinBabler 59 9/1/2021 9/1/2021
Chief Financial Officer John R.Schroer 58 5/1/2022 5/1/2022
Senior Vice President - People and Culture DerrickRichardson 54 6/1/2023 6/1/2023
10 additional Officers and Directors records available in full report.

Business Names
Business Name
ALMS
ALUMIS INC

General Information
Number of Employees: 128 (As of 6/30/2024)
Outstanding Shares: 54,403,302 (As of 8/7/2024)
Stock Exchange: NASD
Fax Number: (302) 531-3150
Email Address: info@alumis.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, October 10, 2024